Fundraising Fox
Aridis Pharmaceuticals
San Jose, US · Delaware corporation
Find your way into Aridis Pharmaceuticals
Sign up to see every warm intro you have to Aridis Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aridis Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aridis Pharmaceuticals is a late-stage clinical biopharmaceutical company developing monoclonal antibody and small-molecule anti-infectives for life-threatening viral and bacterial respiratory infections. Its pipeline targets antimicrobial-resistant bacteria and viral pandemics, using a platform that discovers human monoclonal antibodies from convalescent patients.
Founders & leadership
VL
Vu L. Truong, Ph.D.Founder, CEO and Director
FK
Fred KurlandChief Financial Officer
JB
John BorgesonChief Financial Officer (Acting)
Board
CG
Craig GibbsBoard director
EP
Eric PatzerChairman of the Board of Directors
RC
Robert CoughlinBoard director
JH
John HamiltonBoard director
Reported raises · per SEC filings
Form D private placements$56.6M disclosed across 7 rounds · 2014–2022
▶$4.8MraisedDec 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedDec 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric PatzerDirector
- Susan Windham-BannisterDirector
- John HamiltonDirector
- Fred KurlandExecutive Officer
- Robert RuffoloDirector
- Craig GibbsDirector
- Vu TruongExecutive Officer
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedOct 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedOct 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vu TruongExecutive Officer, Director
- Susan Windham-BannisterDirector
- Robert Ruffolo, Jr.Director
- Fred KurlandExecutive Officer
- Eric PatzerExecutive Officer, Director
- John HamiltonDirector
- Craig GibbsDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MraisedOct 2020 · 8 investors · PharmaceuticalsRule 506(b)
▶$8.4MraisedOct 2020 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric PatzerExecutive Officer, Director
- Mike NazakExecutive Officer
- Susan Windham-BannisterDirector
- John HamiltonDirector
- Robert Ruffolo, Jr.Director
- Vu TroungExecutive Officer, Director
- Craig GibbsDirector
- Offering amount
- $8.4M
- Amount sold
- $8.4M
- Sales commissions
- $590K
- Placement agents
- Arcadia Securities, LLC, Cantor Fitzgerald & Co.
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.6MraisedDec 2016 · 14 investors · PharmaceuticalsRule 506(b)
▶$13.6MraisedDec 2016 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Craig GibbsDirector
- Fred KurlandExecutive Officer
- Isaac BlechDirector
- John HamiltonDirector
- Robert CoughlinDirector
- Robert Ruffolo, Jr.Director
- Paul-Andre de LameExecutive Officer
- Vu TroungExecutive Officer, Director
- Eric PatzerExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $13.6M
- Minimum investment
- $25K
- Sales commissions
- $1.4M
- Placement agents
- Maxim Merchant Capital, a division of Maxim Group LLC
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.2MraisedAug 2016 · 133 investors · PharmaceuticalsRule 506(b)
▶$15.2MraisedAug 2016 · 133 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert K. CoughlinDirector
- Fred KurlandExecutive Officer
- John HamiltonDirector
- Eric PatzerExecutive Officer, Director
- Vu TruongExecutive Officer, Director
- Robert R. Ruffolo, Jr.Director
- Isaac BlechDirector
- Craig GibbsDirector
- Paul-Andre de LameExecutive Officer
- Offering amount
- $40M
- Amount sold
- $15.2M
- Minimum investment
- $50K
- Sales commissions
- $1.5M
- Placement agents
- Maxim Merchant Capital, a division of Maxim Group LLC
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2015 · 6 investors · PharmaceuticalsRule 506(b)
▶$3MraisedNov 2015 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vu TruongExecutive Officer, Director
- Craig GibbsDirector
- Eric PatzerDirector
- Robert CoughlinDirector
- Fred KurlandExecutive Officer
- Paul-Andre de LameExecutive Officer
- John HamiltonDirector
- Offering amount
- $3.5M
- Amount sold
- $3M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedJul 2014 · 9 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedJul 2014 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vu TruongExecutive Officer, Director
- Fred KurlandDirector
- John BorgesonExecutive Officer
- Eric PatzerDirector
- Robert CoughlinDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Minimum investment
- $250K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Adial PharmaceuticalsAdial Pharmaceuticals is a biopharmaceutical company developing treatments for addiction and inflammatory disease, including AT177, a colon-targeted AhR agonist for ulcerative colitis, and AD04, a genetically targeted serotonin-3 receptor antagonist in Phase 3 trials for Alcohol Use Disorder. It is publicly listed on Nasdaq under the ticker ADIL.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
ANI PharmaceuticalsANI Pharmaceuticals is a generic and specialty pharmaceutical company that develops, manufactures, and distributes prescription drugs across multiple therapeutic areas including generics, rare diseases, and established branded products.
Companies working in the same space as Aridis Pharmaceuticals.
Frequently asked questions
- What does Aridis Pharmaceuticals do?
- Aridis Pharmaceuticals is a late-stage clinical biopharmaceutical company developing monoclonal antibody and small-molecule anti-infectives for life-threatening viral and bacterial respiratory infections. Its pipeline targets antimicrobial-resistant bacteria and viral pandemics, using a platform that discovers human monoclonal antibodies from convalescent patients.
- Who founded Aridis Pharmaceuticals?
- Aridis Pharmaceuticals was founded by Vu Truong, Vu L. Truong, Ph.D..
- How much funding has Aridis Pharmaceuticals raised?
- Aridis Pharmaceuticals has disclosed $56.6M raised across 7 rounds.
- Where is Aridis Pharmaceuticals headquartered?
- Aridis Pharmaceuticals is headquartered in San Jose, US.